

Docket No.: TEX4542P0403US

Remarks

The present invention relates to carboxylic acid derivatives that inhibit the binding of integrins to their receptors.

The Office Action rejected claims 1-19, 25, 26, 30 and 31 under 35 U.S.C. §112, first paragraph "because the specification does not reasonably provide enablement for the radicals R1, R4, R5 forming all heterocycll, heterocyclalkyl or alkylheterocycll rings or when A is NR6, A, Y=CR1, R1 and R6 coming together to form all possible rings." Claims 20-24 and 27-29 have been withdrawn from consideration.

Applicants have amended claims 1, 2, 4, 5, 7, 8, 10, 12, 14 and 17 to delete the terms "heterocycll, heterocyclalkyl and alkylheterocycll" and to delete the phase "and wherein A is NR⁶ and at least one Y is CR¹, R¹ and R⁶ together may form a ring" which appear to be the basis for the Section 112, first paragraph rejection.

Applicants have, where appropriate, substituted the rings "1, 4-oxazinan-4-yl, 4-methyltetrahydro-1(2H)-pyrazinyl and 1-azetanyl" in claims 1, 4, 10 and 12. Support for these rings may be found at page 133, sixth compound; page 135, fourth compound; and page 136, sixth compound. Applicants have also inserted the definition of R²² into claim 10. Support for R²² = hydroxy may be found at page 9, line 8 and page 136, third compound.

Applicants have also amended the specification at page 34. Support for this addition may be found at page 135, fourth compound.

The amendments to claim 1, 4, 7, 10, 12, 14 and 17 directly address and overcome the Section 112, first paragraph, rejection. As noted above, there is no new matter in any of these


Docket No.: TEX4542P0403US

amendments and this rejection should be withdrawn. Furthermore, this rejection does not apply to claims 25 and 26, which are directed to specific compounds.

Favorable consideration and allowance of claims 1-19, 25, 26, 30 and 31 as presently amended is respectfully requested.

Respectfully submitted,

By:



Martin L. Katz, Reg. No. 25,011


Dated: September 25, 2003

Citicorp Center, Suite 3800
500 W. Madison Street
Chicago, IL 60661-2511
Telephone: (312) 876-1800
Facsimile: (312) 876-2020

Docket No.: TEX4542P0403US

Certificate of Mailing

I hereby certify that this correspondence is being deposited with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P. O. Box 1450, Alexandra, VA 22313-1450.


Rebecca J. Willis

Rebecca J. Willis